Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11680090 Interleukin-2 fusion proteins and uses thereof

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Medicenna Therapeutics Corp.

0

Current Assignee

Medicenna Therapeutics Corp.

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

June 20, 2023

0

Patent Application Number

169920680

Date Filed

August 12, 2020

0

Patent Citations

US Patent 8337850 4-1BB binding molecules

0

US Patent 8962804 Meditopes and meditope-binding antibodies and uses thereof

0

US Patent 9428567 Antagonists of interleukin-2 receptor

0

US Patent 10781242 Interleukin-2 fusion proteins and uses thereof

0

US Patent 9468678 Method of producing 4-1BB binding molecules and associated nucleic acids

0

US Patent 7569215 Mutant interleukin-2 (IL-2) polypeptides

0

US Patent 7741465 Chimeric receptor genes and cells transformed therewith

0

US Patent 7943743 Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

0

...

Patent Primary Examiner

Bridget E Bunner

0

CPC Code

0

0

0

0

0

0

0

0

The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11680090 Interleukin-2 fusion proteins and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool